Navigation Links
New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
Date:9/7/2008

(Toronto, ON, September 8, 2008) In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.

"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. "There is currently no available therapy for type 2 diabetes that patients can receive once a week."

The new treatment, Exenatide once weekly is the first in a new class of long-acting medications that mimic the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating. The report compared outcomes for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week, as in the currently available version of the drug known as Exenatide (Byetta).

In an international multicentre 6-month clinical trial involving 300 eligible patients, 75 per cent of study subjects who received the once-weekly Exenatide got their diabetes under control as defined by reaching target glucose levels. Patients treated with Exenatide once weekly also experienced fewer side effects, had no increased risk of hypoglycemia (decrease in blood sugars) and saw reductions in body weight.

Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple drugs based on GLP-1 action are under active clinical development, and the new once-weekly treatment is expected to undergo Canadian regulatory review as early as 2009.

"Biomedical research reaches patients and improves lives," said Dr. Jim Woodgett, Director of Research at the Samuel Lunenfeld Research Institute. "Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery
'/>"/>

Contact: Nikki Luscombe
luscombe@lunenfeld.ca
416-586-4800 x2046
Samuel Lunenfeld Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landmark study opens door to new cancer, aging treatments
2. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. Why a common treatment for prostate cancer ultimately fails
5. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
6. Childrens national co-leads nationwide study of landmark sickle cell treatment
7. Potatoes may hold key to Alzheimers treatment
8. Blood pressure response to daily stress provides clues for better hypertension treatment
9. Genes newly explained effect on height may change tumor disorder treatment
10. Songbirds may hold key to advances in treatment of brain degeneration
11. Treatment corrects severe insulin imbalance in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... BOSTON , July 23, 2014 ... and threat detection, announced today it has been named ... . The Market Guide replaces Gartner,s well-known Magic Quadrant ... Gartner categorized BioCatch as one of several vendors to ... biometric analysis will become a standard feature of at ...
(Date:7/23/2014)... SUP05 will play an increasingly important role in carbon ... minimum zones expand, according to research published this week ... Sciences . , University of British Columbia researchers plumbed ... Inlet, to chart how microbial community metabolism changes as ... very detailed picture of how SUP05 a bacterial ...
(Date:7/23/2014)...   MedNet Solutions , a global life ... systems, is pleased to announce that M. ... executive with over 25 years of experience, has ... be responsible for MedNet,s day-to-day operating activities, driving ... product/service delivery.  "We welcome Clareece, ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2MedNet Appoints Clareece West As Chief Operating Officer 2
... of Technology have developed a miniature sensor that uses ... measure pollutants present in aqueous or gaseous environments. An ... be used during field-testing to rapidly detect many different ... allows water and air samples to be analyzed in ...
... using flexible electronics for next-generation biomedical devices has ... research program at Cornell, funded by the National ... received $3.2 million over five years from NSF,s ... Recruited IGERT fellows will work in teams to ...
... of a new approach to discover life on Mars ... a twelve-day, low-Earth orbit experiment to assess their survivability ... Mars. The new approach is based on technology ... so-called immunoassays are embodied in the Life Marker Chip ...
Cached Biology News:New microsensor measures volatile organic compounds in water and air on-site 2New microsensor measures volatile organic compounds in water and air on-site 3IGERT fellows to design biodevices using flexible electronics 2Life on Mars 'pregnancy test' successfully launched 2
(Date:7/23/2014)... Heroic worldwide conservation efforts have made great strides in ... in China, there are over 65 giant panda reserves ... But despite these efforts, just 1596 pandas remain in ... and zoos hope to save the panda by improving ... to the wild. Just how are these high-profile programs ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks ... performance for the long term. They are the first ... of sustained energy as an alternative to the temporary ... Drinks on Indiegogo on July 29, 2014, with hopes ... campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... 2014 Last year, Formedix ... leading global provider of data management solutions for clinical ... leading-edge system for electronic data capture (EDC) and clinical ... and study execution tools added TrialMaster to its Transform ... version of Transform for TrialMaster, is being released this ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3
... data reported for the first time show that ... (golimumab) resulted in significantly greater inhibition of structural ... with active rheumatoid arthritis (RA) and active psoriatic ... with SIMPONI resulted in a statistically significant reduction ...
... Oct. 19 Encorium Group, Inc. (Nasdaq: ENCO ... provides design, development, and management capabilities for clinical trials ... pharmaceutical companies, today announced that it has completed a ... with a private investor for an aggregate purchase price ...
... ... Data Analysis in Biomarker Project , ... Basel, Switzerland (PRWEB) October 19, 2009 -- Genedata, a leading provider ... collaboration with the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, ...
Cached Biology Technology:New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 2New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 3New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 4New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 5New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 6New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 7New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 8New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 9New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 10New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 11New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis 12Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 2Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 3Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 4Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY 5Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4
... Enhancing signals in immunostaining ,This solution has ... allows to get clearer signal than the ... reduce the amount of secondary antibody used ... accordingly you can have images with high ...
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
... exists predominantly as XDH which converts hypoxanthine ... plasma antioxidant. During ischemia, XDH is ... XO by oxidation of essential sulfhydryl groups ... the amino-terminus. AO has a higher ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: